DexCom

DXCM

Market cap $28.5B

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help with healthy weight loss, the first of its kind to be cleared by the FDA in 2025.

Medical device maker Dexcom said on Tuesday some of its glucose sensors ​slated for destruction were instead stolen and ‌sold, prompting the company to warn users not to use products from two affected lots.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company's quality control process. Sensors identified.

Dexcom (DXCM) is leveraging AI to drive operational efficiency and product innovation, positioning itself as a platform medical provider in CGM. DXCM achieved 300 basis points in operating margin improvement, with sustained cost savings and strong FCF margin outpacing healthcare equipment peers. Stelo CGM, built with Google AI, targets the large prediabetic market, offering significant customer base expansion potential without requiring a prescription.

DexCom is now rated a 'Buy' as improved fundamentals and a 15% lower stock price present a more attractive entry. Q1/26 results showed 15% revenue growth, and 90.9% operating income growth and raised 2026 guidance for both revenue and margins. Key growth drivers include international expansion, increased U.S. coverage for type 2 diabetics, and a $1B share buyback in 2026.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. D.

DexCom NASDAQ: DXCM used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement.